Article

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognition

2024-12-04

Abstract excerpt

<title>Abstract</title> <p>Background: T cell receptor (TCR)–engineered T cells targeting neoantigens originated from mutations in KRAS gene have demonstrated promising outcomes in clinical trials against solid tumors. However, the challenge lies in developing tumor-specific TCRs that avoid cross-reactivity with self-antigens to minimize the possibility of severe clinical toxicities. Current research efforts have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a77a7e8b-c314-56ce-af97-bfb02ff6b52f
DOI: 10.21203/rs.3.rs-5223285/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionDOI 10.21203/rs.3.rs-5223285/v1Read

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.Semantic proximity Read

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read

Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activitySemantic proximity Read

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read

Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Semantic proximity Read

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read